First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Titel:
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Auteur:
Peters, S. Scherpereel, A. Cornelissen, R. Oulkhouir, Y. Greillier, L. Kaplan, M.A. Talbot, T. Monnet, I. Hiret, S. Baas, P. Nowak, A.K. Fujimoto, N. Tsao, A.S. Mansfield, A.S. Popat, S. Zhang, X. Hu, N. Balli, D. Spires, T. Zalcman, G.